JP2004535461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004535461A5 JP2004535461A5 JP2003513312A JP2003513312A JP2004535461A5 JP 2004535461 A5 JP2004535461 A5 JP 2004535461A5 JP 2003513312 A JP2003513312 A JP 2003513312A JP 2003513312 A JP2003513312 A JP 2003513312A JP 2004535461 A5 JP2004535461 A5 JP 2004535461A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- peptide
- alanine
- copper
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 67
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 60
- 238000000034 method Methods 0.000 claims 54
- ZRPDXDBGEYHEBJ-UHFFFAOYSA-N alpha-(hydroxymethyl)serine Chemical compound OCC(N)(CO)C(O)=O ZRPDXDBGEYHEBJ-UHFFFAOYSA-N 0.000 claims 52
- 239000010949 copper Substances 0.000 claims 35
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 34
- 229960003767 alanine Drugs 0.000 claims 34
- 235000004279 alanine Nutrition 0.000 claims 34
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims 33
- 229910052802 copper Inorganic materials 0.000 claims 33
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 31
- 229960005261 aspartic acid Drugs 0.000 claims 31
- 235000003704 aspartic acid Nutrition 0.000 claims 31
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 31
- 239000004475 Arginine Substances 0.000 claims 30
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 30
- 239000004471 Glycine Substances 0.000 claims 30
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 30
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 30
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 30
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 30
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 30
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 30
- 229960003121 arginine Drugs 0.000 claims 30
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 30
- 235000009697 arginine Nutrition 0.000 claims 30
- 229960002989 glutamic acid Drugs 0.000 claims 30
- 235000013922 glutamic acid Nutrition 0.000 claims 30
- 239000004220 glutamic acid Substances 0.000 claims 30
- 229960002449 glycine Drugs 0.000 claims 30
- 229960004295 valine Drugs 0.000 claims 30
- 239000004474 valine Substances 0.000 claims 30
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 28
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 28
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 28
- 239000004472 Lysine Substances 0.000 claims 28
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 28
- 239000004473 Threonine Substances 0.000 claims 28
- 229960001230 asparagine Drugs 0.000 claims 28
- 235000009582 asparagine Nutrition 0.000 claims 28
- 229960003646 lysine Drugs 0.000 claims 28
- 229960002898 threonine Drugs 0.000 claims 28
- 235000008521 threonine Nutrition 0.000 claims 28
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical group [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims 24
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 24
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims 24
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 24
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 24
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 24
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 24
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 24
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 24
- 229940024606 amino acid Drugs 0.000 claims 24
- 235000001014 amino acid Nutrition 0.000 claims 24
- 150000001413 amino acids Chemical class 0.000 claims 24
- 229910001431 copper ion Inorganic materials 0.000 claims 24
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 24
- 229960002743 glutamine Drugs 0.000 claims 24
- 235000004554 glutamine Nutrition 0.000 claims 24
- 229960003136 leucine Drugs 0.000 claims 24
- 229960003104 ornithine Drugs 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 24
- 229960004799 tryptophan Drugs 0.000 claims 24
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 21
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 21
- 229960001153 serine Drugs 0.000 claims 21
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 20
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 20
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 20
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 20
- 239000002738 chelating agent Substances 0.000 claims 20
- 125000000524 functional group Chemical group 0.000 claims 20
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 20
- 229960002885 histidine Drugs 0.000 claims 20
- 229960000310 isoleucine Drugs 0.000 claims 20
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 20
- 229930182817 methionine Natural products 0.000 claims 20
- 239000002184 metal Substances 0.000 claims 18
- 229910052751 metal Inorganic materials 0.000 claims 18
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims 16
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 16
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 16
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 16
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 16
- 235000018417 cysteine Nutrition 0.000 claims 16
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims 16
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims 16
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 16
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 16
- 101800004937 Protein C Proteins 0.000 claims 15
- 101800001700 Saposin-D Proteins 0.000 claims 15
- 102400000827 Saposin-D Human genes 0.000 claims 15
- 229960000856 protein c Drugs 0.000 claims 15
- 229940000635 beta-alanine Drugs 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 8
- 102000035195 Peptidases Human genes 0.000 claims 8
- 108091005804 Peptidases Proteins 0.000 claims 8
- 239000002253 acid Substances 0.000 claims 8
- BBJIPMIXTXKYLZ-UHFFFAOYSA-N isoglutamic acid Chemical compound OC(=O)CC(N)CC(O)=O BBJIPMIXTXKYLZ-UHFFFAOYSA-N 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims 8
- UWQDKRIZSROAKS-FJXKBIBVSA-N Gly-Met-Thr Chemical compound [H]NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O UWQDKRIZSROAKS-FJXKBIBVSA-N 0.000 claims 6
- 230000015572 biosynthetic process Effects 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 238000003786 synthesis reaction Methods 0.000 claims 5
- SLHOOKXYTYAJGQ-XVYDVKMFSA-N Asp-Ala-His Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 SLHOOKXYTYAJGQ-XVYDVKMFSA-N 0.000 claims 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- PLBJMUUEGBBHRH-ZLUOBGJFSA-N Cys-Ala-Asn Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O PLBJMUUEGBBHRH-ZLUOBGJFSA-N 0.000 claims 4
- 150000008574 D-amino acids Chemical class 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims 4
- 101710111620 Protein C activator Proteins 0.000 claims 4
- 125000003636 chemical group Chemical group 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 229960004452 methionine Drugs 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 claims 2
- PFMUCCYYAAFKTH-YFKPBYRVSA-N Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CN PFMUCCYYAAFKTH-YFKPBYRVSA-N 0.000 claims 2
- RITKHVBHSGLULN-WHFBIAKZSA-N L-gamma-glutamyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(O)=O RITKHVBHSGLULN-WHFBIAKZSA-N 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 208000014171 autosomal dominant thrombophilia due to protein C deficiency Diseases 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 108010004073 cysteinylcysteine Proteins 0.000 claims 2
- 108010068906 gamma-glutamylcysteine Proteins 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 230000002209 hydrophobic effect Effects 0.000 claims 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 2
- 201000005665 thrombophilia Diseases 0.000 claims 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 1
- 244000003416 Asparagus officinalis Species 0.000 claims 1
- 235000005340 Asparagus officinalis Nutrition 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000019253 formic acid Nutrition 0.000 claims 1
- 229940013688 formic acid Drugs 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30700501P | 2001-07-19 | 2001-07-19 | |
| US34451401P | 2001-12-28 | 2001-12-28 | |
| PCT/US2002/022951 WO2003007686A2 (en) | 2001-07-19 | 2002-07-19 | Use of copper chelators to inhibit the inactivation of protein c |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004535461A JP2004535461A (ja) | 2004-11-25 |
| JP2004535461A5 true JP2004535461A5 (https=) | 2006-04-20 |
Family
ID=26975490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003513312A Pending JP2004535461A (ja) | 2001-07-19 | 2002-07-19 | プロテインｃの不活性化を抑制するための銅キレート剤の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20030055003A1 (https=) |
| EP (1) | EP1417055A4 (https=) |
| JP (1) | JP2004535461A (https=) |
| AU (1) | AU2002354951A1 (https=) |
| WO (1) | WO2003007686A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1115389B1 (en) * | 1998-09-25 | 2014-03-12 | PhilERA New Zealand Limited | Fructosamine oxidase: antagonists and inhibitors |
| US7592304B2 (en) | 1999-10-01 | 2009-09-22 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| US20030158111A1 (en) * | 1999-10-01 | 2003-08-21 | David Bar-Or | Methods and products for oral care |
| US7632803B2 (en) | 1999-10-01 | 2009-12-15 | Dmi Life Sciences, Inc. | Metal-binding compounds and uses therefor |
| ATE555782T1 (de) | 2002-03-08 | 2012-05-15 | Philera New Zealand Ltd | Prävention und/oder behandlung von kardiovaskulären erkrankungen und/oder damit zusammenhängender herzinsuffizienz |
| AU2003213146A1 (en) * | 2002-03-08 | 2003-09-22 | Eli Lilly And Company | Activated protein c formulations |
| US20060100278A1 (en) | 2002-08-20 | 2006-05-11 | Cooper Garth J S | Dosage forms and related therapies |
| US20070258970A1 (en) * | 2003-12-09 | 2007-11-08 | Robert Blumenthal | Methods for Inhibiting Hiv and Other Viral Infections by Modulating Ceramide Metabolism |
| US8193291B2 (en) * | 2004-02-23 | 2012-06-05 | Caiteng Zhang | Solution of metal-polymer chelate(s) and applications thereof |
| ES2449066T3 (es) | 2004-07-19 | 2014-03-18 | Philera New Zealand Limited | Síntesis de trietilentetraminas |
| JP5103748B2 (ja) * | 2005-02-16 | 2012-12-19 | 東レ株式会社 | 医薬組成物 |
| WO2006104402A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
| WO2006104398A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Copper antagonist compositions |
| EP2006271A4 (en) | 2006-03-30 | 2011-08-10 | Asahi Kasei Pharma Corp | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF |
| EP2272832A4 (en) | 2008-04-28 | 2011-09-07 | Asahi Kasei Pharma Corp | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF |
| JP5265762B2 (ja) | 2008-05-13 | 2013-08-14 | ユニバーシティ・オブ・カンザス | 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法 |
| WO2013181461A2 (en) | 2012-06-01 | 2013-12-05 | University Of Kansas | Metal abstraction peptide with superoxide dismutase activity |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4461724A (en) * | 1981-10-28 | 1984-07-24 | Nippon Zoki Pharmaceutical Co., Ltd. | Peptide compounds, a process for manufacturing them, pharmaceutical compositions containing them, and methods for treating ulcer and thrombus with them |
| US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| WO1988006457A1 (fr) * | 1987-03-04 | 1988-09-07 | Nippon Hypox Laboratories Incorporated | Composition medicinale contenant de l'albumine en tant que support et procede de preparation |
| JP2739050B2 (ja) * | 1988-01-28 | 1998-04-08 | ヘキスト薬品工業株式会社 | 抗血液凝固剤 |
| US5270447A (en) * | 1988-05-20 | 1993-12-14 | The United States Of America As Represented By The Department Of Health & Human Services | Metalloproteinase peptides: role in diagnosis and therapy |
| US4981952A (en) * | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5093117A (en) * | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| ATE163048T1 (de) * | 1989-12-29 | 1998-02-15 | Zymogenetics Inc | Hybrides protein c |
| JPH0813750B2 (ja) * | 1990-03-01 | 1996-02-14 | 持田製薬株式会社 | 経口用トロンビン製剤 |
| US5571786A (en) * | 1990-08-16 | 1996-11-05 | Immuno Aktiengesellschaft | Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation |
| WO1994014836A1 (en) * | 1992-12-18 | 1994-07-07 | Centocor, Inc. | Peptide inhibitors of selectin binding |
| DE4320294A1 (de) * | 1993-06-18 | 1994-12-22 | Immuno Ag | Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen |
| JP3043558B2 (ja) * | 1993-10-29 | 2000-05-22 | 財団法人化学及血清療法研究所 | ヒト活性化プロテインｃ調製物及びその製法 |
| US5538945A (en) * | 1994-06-17 | 1996-07-23 | Procyte Corporation | Stimulation of hair growth by peptide copper complexes |
| UA55448C2 (uk) * | 1997-04-28 | 2003-04-15 | Елі Ліллі Енд Компані | Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| ATE203567T1 (de) * | 1998-03-19 | 2001-08-15 | Instrumentation Lab Spa | Verbesserte in vitro verfahren, testkits und reagenzien zum screening von blutgerinnungsfehlern |
| US5932548A (en) * | 1998-06-03 | 1999-08-03 | Deghenghi; Romano | Lysine containing peptides for treatment of heart disease |
| WO2000023101A1 (en) * | 1998-10-22 | 2000-04-27 | Eli Lilly And Company | Methods for treating sepsis |
-
2002
- 2002-07-19 US US10/199,285 patent/US20030055003A1/en not_active Abandoned
- 2002-07-19 AU AU2002354951A patent/AU2002354951A1/en not_active Abandoned
- 2002-07-19 WO PCT/US2002/022951 patent/WO2003007686A2/en not_active Ceased
- 2002-07-19 JP JP2003513312A patent/JP2004535461A/ja active Pending
- 2002-07-19 EP EP02752462A patent/EP1417055A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004535461A5 (https=) | ||
| JPH0532696A (ja) | 副甲状腺ホルモン誘導体 | |
| JP2024520861A (ja) | 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体 | |
| EP2030984A4 (en) | DERIVED FROM SPARC CANCER EXHAUSTANTEPEPTIDE AND PHARMACEUTICALS CONTAINING THEREOF | |
| JP2004521123A5 (https=) | ||
| WO2018236931A1 (en) | Peptide compositions and related methods | |
| CN116669752B (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| CN116710114B9 (zh) | Glp-1/glp-2双重激动剂的药物组合物 | |
| JP2003073400A (ja) | 骨形成作用を有する新規なペプチドおよびこれを固定化してなる骨形成促進剤 | |
| JPWO2020120983A5 (https=) | ||
| CA2351558A1 (en) | Peptide fragments having cell death inhibitory activity | |
| RU2010128602A (ru) | Циклический белок, не содержащий остатков цистеина | |
| JP2019038772A5 (https=) | ||
| JP2003528814A5 (https=) | ||
| US20030139345A1 (en) | Synthetic peptides and methods for treating cancer invasion and metastasis | |
| JP3726875B2 (ja) | 歯周病細菌内毒素中和剤、歯周病原因菌付着抑制剤及び口腔用組成物 | |
| JP4470152B2 (ja) | 新規トリペプチドおよびその製造方法 | |
| KR101025352B1 (ko) | 생리활성 복합체 | |
| KR20140049628A (ko) | 안지오텐신 전환 효소 저해 활성을 갖는 펩타이드 | |
| CA3022763A1 (en) | Novel peptides and peptidomimetics | |
| CA2558985A1 (en) | Erythropoietin liquid formulation | |
| JP2005517636A5 (https=) | ||
| JP2967956B2 (ja) | ペプチドまたはその塩 | |
| JPH0782172A (ja) | 創傷治療剤 | |
| JPH10139797A (ja) | ペプチドおよびその塩 |